Medical team performs a minimally invasive procedure in an operating room with endoscopic images displayed on monitors
A CARTISTEM® procedure at St. Luke's Hospital in Seoul. St. Luke's Hospital

SEOUL, South Korea — For people with knee arthritis, damaged cartilage has long been a one-way problem. Cartilage has almost no blood supply, so once it wears away, it does not grow back on its own. Most treatments aim to ease the pain rather than repair the tissue.

CARTISTEM® takes a different approach. Approved in South Korea since 2012, it is made from donated umbilical cord blood stem cells and is applied directly to an area of damaged cartilage during surgery. Its goal is to help that area fill in with new cartilage-like tissue. More than 36,000 patients have received it in Korea, according to the manufacturer.

"CARTISTEM gives us something we did not have before: a way to treat the cartilage defect itself, not just the symptoms," said Yeong Seok Lee, M.D., Ph.D., an orthopedic surgeon at St. Luke's Hospital in Seoul. "For the right patient, it can be a meaningful step before a knee replacement."

What the research shows. In the Korean Phase 3 trial, published in the Orthopaedic Journal of Sports Medicine, 114 patients with large, full-thickness cartilage defects were randomly assigned to CARTISTEM or microfracture, a standard cartilage procedure. At 48 weeks, a second-look arthroscopy found that cartilage had improved by at least one grade in 97.7% of the CARTISTEM group, compared with 71.7% of the microfracture group.

During extended follow-up of three to five years, the CARTISTEM group also reported better pain and knee function than the microfracture group, suggesting that the benefit held up over time.

Japan: Phase 3 complete. In May 2026, the manufacturer reported results from a Phase 3 trial of 130 patients with moderate to severe knee osteoarthritis at 13 hospitals in Japan, comparing CARTISTEM with hyaluronic acid injections over 52 weeks. The company said CARTISTEM met both co-primary endpoints — a patient-reported pain and function score, and cartilage repair confirmed by second-look arthroscopy — as well as all secondary endpoints. It plans to apply for approval in Japan by the end of 2026, with approval targeted for 2027.

United States: Phase 3 under way. The FDA cleared the U.S. trial in February 2026 and in June agreed that a single pivotal study could support an application for approval. The randomized, double-blind trial treated its first patient in July 2026 and plans to enroll 300 adults with Kellgren-Lawrence grade 2–3 arthritis at about 70 sites in the United States and Canada, comparing CARTISTEM with surgical debridement. Enrollment is expected to take about two years, followed by two years of follow-up, so results are not yet available. CARTISTEM is not FDA-approved for commercial use.

CARTISTEM® milestones in Korea, Japan and the United States. Graphic: St. Luke's Hospital

How the treatment works. The procedure is done in the operating room in one session:

1. Confirm the damage. The surgeon looks inside the knee to confirm the size and location of the cartilage defect.

2. Prepare the area. Under anesthesia given by a full-time anesthesiologist, the surgeon makes small holes in the damaged area.

3. Apply CARTISTEM. The donor stem cells are placed into the defect. No tissue is harvested from the patient's own body.

Recovery takes commitment. Patients typically use crutches for about two to three months and continue rehabilitation for about a year. Overseas patients should plan on a stay of about four weeks in Seoul; the final plan is set after an individual review. More detail is available in the hospital's guide to CARTISTEM surgery and recovery.

Who may be a candidate. CARTISTEM is generally considered for people with stage 2–3 knee arthritis and a defined area of deep cartilage damage, often confirmed on MRI. It is usually not suitable for severe, bone-on-bone arthritis across the whole joint, or for knees with significant misalignment that needs to be corrected first.

"The best results come from choosing the right candidate," Dr. Lee said. "That starts with a careful look at the MRI and an honest conversation about the recovery. When the damage is in the right place and the patient is ready for the rehabilitation, this is a treatment I am glad to be able to offer."

At St. Luke's Hospital, MRI scans are taken on site and read the same day by a full-time radiologist. Because the same orthopedic team also offers bone marrow injection and joint replacement, patients can compare their options before deciding.

Patients in the United States can send recent X-rays or MRI images for a review from home or email [email protected]. The team replies in English within three business days, and consultations are held directly in English with Dr. Lee.

Regulatory note: CARTISTEM® is approved for specific uses in South Korea. It is not FDA-approved for commercial use in the United States. Treatment suitability, expected benefits, limitations, risks, and alternatives should be reviewed individually.

Next in the series (November 24): A step-by-step approach before knee replacement.

About Yeong Seok Lee, M.D., Ph.D. Dr. Lee is an orthopedic surgeon focused on knee and shoulder care and a Clinical Professor at Sungkyunkwan University School of Medicine (Samsung Medical Center). His research has appeared in The American Journal of Sports Medicine and the Journal of Shoulder and Elbow Surgery.

About St. Luke's Hospital. St. Luke's Hospital is a multi-specialty hospital in Seoul, open 365 days a year, with full-time radiology and anesthesiology specialists and an in-house MRI on site, and about an hour from Incheon International Airport. Its Stem Cell & Joint Preservation Center offers knee care ranging from injections to cartilage procedures and joint replacement.

Media contact: International Team, St. Luke's Hospital · [email protected]

This release is for general information and is not medical advice. Individual results vary.

###